Literature DB >> 8461680

Experience with screening newborns for Duchenne muscular dystrophy in Wales.

D M Bradley1, E P Parsons, A J Clarke.   

Abstract

OBJECTIVES: To assess the acceptability of screening newborn boys for Duchenne muscular dystrophy.
DESIGN: Screening is offered on the basis of informed consent in response to an information sheet entitled "A new test for baby boys--Do you want it?" The programme includes a prospective long term evaluation of family responses to early diagnosis and a comparison of their experiences and perceptions with those families who have undergone the later traditional clinical diagnosis.
SETTING: All maternity units throughout Wales. Samples obtained through screening programme for phenylketonuria and congenital hypothyroidism.
SUBJECTS: Those families whose son had a positive screening test. MAIN OUTCOME MEASURES: Creatine kinase activity. Venous blood test to confirm positive result. Molecular genetic mutation analysis. Muscle biopsy and dystrophin analysis. Qualitative measure of satisfaction among affected families.
RESULTS: 34,219 Boys have been screened and nine affected families have been identified. Eight families were very positive about the programme. Three chose not to complete the diagnostic process.
CONCLUSION: The programme should continue to permit a full evaluation of the issues involved and should serve as a model for other initiatives within the community for genetic disease.

Entities:  

Keywords:  Empirical Approach; Genetics and Reproduction

Mesh:

Substances:

Year:  1993        PMID: 8461680      PMCID: PMC1676471          DOI: 10.1136/bmj.306.6874.357

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  12 in total

1.  Attitudes of mothers to neonatal screening for Duchenne muscular dystrophy.

Authors:  R A Smith; D K Williams; J R Sibert; P S Harper
Journal:  BMJ       Date:  1990-04-28

2.  False positive creatine kinase test in hypothyroid male at risk for Duchenne muscular dystrophy.

Authors:  H Williams; I Hughes; P S Harper; D Bradley
Journal:  Lancet       Date:  1984-09-15       Impact factor: 79.321

3.  Feasibility of neonatal screening for Duchenne muscular dystrophy.

Authors:  R Skinner; A E Emery; G Scheuerbrandt; J Syme
Journal:  J Med Genet       Date:  1982-02       Impact factor: 6.318

4.  Muscular dystrophy screening.

Authors:  L M Drummond; A M Veale
Journal:  Lancet       Date:  1978-06-10       Impact factor: 79.321

5.  Intragenic deletions in 164 boys with Duchenne muscular dystrophy (DMD) studied with dystrophin cDNA.

Authors:  M Upadhyaya; R A Smith; N S Thomas; A M Norman; P S Harper
Journal:  Clin Genet       Date:  1990-06       Impact factor: 4.438

6.  Newborn screening for Duchenne muscular dystrophy.

Authors:  H Zellweger; A Antonik
Journal:  Pediatrics       Date:  1975-01       Impact factor: 7.124

7.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

8.  Congenital hydrocephalus secondary to Walker-Warburg syndrome identified on the Manitoba Neonatal Screening Programme for Duchenne muscular dystrophy.

Authors:  C R Greenberg; H K Jacobs; T E Nylen; M Gibb; B N Chodirker; M Moffatt; A Lacson; W Halliday; F Bernier; A el-Husseini
Journal:  J Med Genet       Date:  1992-08       Impact factor: 6.318

9.  Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program.

Authors:  G Scheuerbrandt; A Lundin; T Lövgren; W Mortier
Journal:  Muscle Nerve       Date:  1986-01       Impact factor: 3.217

10.  Coronary heart-disease after treatment of hypertension.

Authors:  G Berglund; R Sannerstedt; O Andersson; H Wedel; L Wilhelmsen; L Hansson; R Sivertsson; J Wikstrand
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

View more
  24 in total

Review 1.  Evidence based case report: Assessing developmental delay.

Authors:  J Dorling; A Salt
Journal:  BMJ       Date:  2001-07-21

Review 2.  Ethical issues in newborn screening and the impact of new technologies.

Authors:  Bridget Wilcken
Journal:  Eur J Pediatr       Date:  2003-11-14       Impact factor: 3.183

3.  Whole body skeletal muscle transduction in neonatal dogs with AAV-9.

Authors:  Yongping Yue; Jin-Hong Shin; Dongsheng Duan
Journal:  Methods Mol Biol       Date:  2011

4.  Telling the parents: newborn blood spot screening for cystic fibrosis.

Authors:  Di Asplin
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

Review 5.  Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening.

Authors:  Yvonne Bombard; Fiona A Miller; Robin Z Hayeems; Denise Avard; Bartha M Knoppers
Journal:  Eur J Hum Genet       Date:  2010-03-03       Impact factor: 4.246

6.  Molecular diagnosis and treatment of two x-linked disorders.

Authors:  Cyril Mamotte
Journal:  Clin Biochem Rev       Date:  2011-08

7.  Disclosure of Duchenne muscular dystrophy after newborn screening.

Authors:  E Parsons; D Bradley; A Clarke
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

Review 8.  Social and psychological issues associated with the new genetics.

Authors:  S Macintyre
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-08-29       Impact factor: 6.237

9.  Newborn screening for Duchenne muscular dystrophy: a psychosocial study.

Authors:  E P Parsons; A J Clarke; K Hood; E Lycett; D M Bradley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-03       Impact factor: 5.747

10.  Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK).

Authors:  Stuart J Moat; Donald M Bradley; Rachel Salmon; Angus Clarke; Louise Hartley
Journal:  Eur J Hum Genet       Date:  2013-01-23       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.